Merz, L., Zon, R., Jacobus, S., Samur, M., Zonder, J., Khan, A., … Richardson, P. (2025). The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. In Blood (Vol. 146, pp. 1033–1033). American Society of Hematology. https://doi.org/10.1182/blood-2025-1033

Merz, Lauren, Rebecca Zon, Susanna Jacobus, Mehmet Samur, Jeffrey Zonder, Abdullah Khan, Hani Hassoun, et al. “The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial.” In Blood, 146:1033–1033. American Society of Hematology, 2025. https://doi.org/10.1182/blood-2025-1033.

Merz L, Zon R, Jacobus S, Samur M, Zonder J, Khan A, et al. The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. In: Blood. American Society of Hematology; 2025. p. 1033–1033.

Merz, Lauren, et al. “The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial.” Blood, vol. 146, no. Supplement 1, American Society of Hematology, 2025, pp. 1033–1033. Crossref, doi:10.1182/blood-2025-1033.

Merz L, Zon R, Jacobus S, Samur M, Zonder J, Khan A, Hassoun H, Anderson L, Efebera Y, Buck T, Innis-Shelton R, Hartley-Brown M, Lonial S, Campagnaro E, Voorhees P, Orlowski R, Costello C, Raje N, Medvedova E, McCarthy P, Milner C, Gasparetto C, Agha M, Gowin K, Kamble R, Jagannath S, Nathwani N, Alsina M, Giralt S, Laubach J, Nadeem O, Ghobrial I, Mo C, Anderson K, Munshi N, Richardson P. The impact of Duffy genotype on progression-free survival (PFS) with lenalidomide, Bortezomib, and dexamethasone (RVd) alone or RVd plus autologous stem cell transplantation (ASCT) and continuous R maintenance in patients (pts) with newly diagnosed multiple myeloma (NDMM): Updated subgroup analysis of the phase 3 DETERMINATION trial. Blood. American Society of Hematology; 2025. p. 1033–1033.